Mont-saint-guibert
MONT-SAINT-GUIBERT, Belgium, September 22, 2011 -
The Belgian biotechnology company, Cardio3 BioSciences, a leader in the discovery and development of regenerative and protective therapies for the treatment of cardiovascular diseases, announced today that it has established a subsidiary, Cardio3 BioSciences, Inc.
MONT-SAINT-GUIBERT, Belgium, April 5, 2011 - The Belgian biotechnology company, Cardio3 BioSciences, a
leader in discovery and development of regenerative and protective therapies
for the treatment of cardiovascular diseases, today presented detailed data
from the Phase II clinical trial of C3BS-CQR-1 (C-Cure(R)), its novel stem
cell therapy for ischemic cardiomyopathy, at the 60th annual American College
of Cardiology in New Orleans, USA.
MONT-SAINT-GUIBERT, Belgium, December 20, 2010 - The Belgian biotechnology company, Cardio3 BioSciences, a leader in the
discovery and development of regenerative and protective therapies for the
treatment of cardiovascular diseases, today announces positive pre-clinical
results from its in-house product candidate C3BS-GQR-1, a "cardiopoietic"
cocktail designed to treat patients suffering from acute myocardial
infarction in order to protect cardiac tissue from damage and direct heart
stem cells to mature and restore pump function.
MONT-SAINT-GUIBERT, Belgium, November 17, 2010 - The Belgian biotechnology company, Cardio3 BioSciences - a
leader in discovery and development of regenerative and protective therapies
for the treatment of cardiovascular diseases - today announces positive
six-month results, including significant functional and clinical benefit,
from the Phase II clinical trial of its development programme C-Cure(R),
designed as a novel stem cell therapy for heart failure based on breakthrough
technology.
MONT-SAINT-GUIBERT, Belgium, August 16, 2010 - Cardio3 BioSciences, a leading Belgian biotechnology company specialising
in regenerative therapies for the treatment of cardiovascular disease, today
announces that the key scientific work underlying its lead pharmaceutical
product C-Cure(R), a revolutionary stem cell treatment for heart failure, has
been published in the Journal of the American College of Cardiology (JACC).
More News
- This press release is issued to clarify a Cardio3 BioSciences release of July 14, 2010.
- Dr. Atta Behfar Recognised With Prestigious Award for Science Behind Cardio3 BioSciences' C-Cure Technology
- Cardio3 BioSciences Reports Positive Three-Month Data From its Clinical Trial of C-Cure(R) in Heart Failure
- Cardio3 BioSciences Announces Promising Pre-Clinical Data for Proprietary C-Cath(R) Catheter
- 45 Patients Enrolled in Study Designed to Evaluate the Ability of Cardiopoietic Cells to Restore Cardiac Function
- Cardio3 BioSciences Presents Update on C-Cure(R) Second Generation Stem Cell Therapy for Heart Failure at European Society of Cardiology Congress
